Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences

Core Insights - Praxis Precision Medicines, Inc. will report its financial results for Q4 and the full year ended December 31, 2025, on February 19, 2026, before the market opens [1] - The company will host a conference call and live webcast on the same day at 8:00 am ET to review the financial results and provide a corporate update [2] - Praxis has a diversified CNS portfolio with multiple programs across movement disorders and epilepsy, including four late-stage product candidates [4] Company Overview - Praxis Precision Medicines is a leading CNS precision neuroscience biopharmaceutical company focused on developing therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance [4] - The company utilizes its proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, to translate genetic insights into therapeutic development [4] - Praxis is actively participating in investor conferences, including the Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026, and the TD Cowen 46th Annual Health Care Conference on March 2, 2026 [5]